Can repeated endoscopic dilatations damage the urethra?

Can repeated endoscopic dilatations damage the urethra?: Endoscopic treatments—blind dilatation, balloon dilatation, and direct-vision internal urethrotomy (DVIU)—are widely used for the initial management of urethral strictures because they are minimally invasive, quick and often effective in the short term. However, repeated endoscopic interventions are associated with high recurrence rates and may alter the stricture’s character, potentially increasing fibrosis, lengthening the stenotic segment, creating false passages, and complicating later reconstructive surgery. Contemporary guidelines increasingly recommend urethroplasty rather than repeated endoscopic procedures for recurrent anterior urethral strictures.

This article examines the pathophysiology of iatrogenic urethral injury from repeated dilatation, critically reviews clinical evidence and systematic reviews, summarizes guideline recommendations, explores evolving adjuncts designed to reduce recurrence (e.g., intralesional agents, drug-coated balloons), and offers practical, evidence-based recommendations for clinicians. Representative studies and guidelines are cited to support key claims.

Introduction — why this question matters

Urethral strictures cause obstructive lower urinary tract symptoms, urinary infections and decreased quality of life. Initial management often favors less invasive measures—dilatation or DVIU—because they rapidly restore lumen patency and are convenient for both patient and clinician. But while these techniques can give prompt symptomatic relief, their long-term durability is limited. Repeated endoscopic dilation or urethrotomy is common in many settings, yet there is growing evidence that multiple consecutive procedures may worsen the underlying disease, increase the technical complexity of later urethroplasty, and add cumulative morbidity. Given the shift in many specialist guidelines toward early definitive reconstruction for recurrent disease, clinicians need a clear, evidence-based understanding of whether—and how—repeated endoscopic dilatations damage the urethra.

Basic concepts: what do we mean by “damage”?

When we discuss “damage” from repeated endoscopic dilatations, we refer to measurable adverse changes in urethral structure and function that influence patient outcomes:

• Increased fibrosis and scarring — denser collagen deposition and loss of normal urethral tissue planes.
• Lengthening or extension of the stricture — a short focal stricture becoming longer or more complex after repeated manipulations.
• Creation of false passages or urethral wall injury — traumatic disruptions leading to extraluminal tracts or localized devitalized tissue.
• Alterations that make later reconstruction more complex — including poorer tissue quality, need for grafts or staged repairs, and higher failure rates.
• Cumulative morbidity — increased risk of infection, bleeding, urethrocutaneous fistula, and impact on urinary and sexual function.

Understanding whether repeated endoscopic procedures cause these changes requires correlating pathophysiology with clinical outcomes from observational studies and guideline evidence.

Mechanisms: how endoscopic dilatation could make a stricture worse

Mechanical trauma and the wound-healing response

All dilatation and incision maneuvers exert mechanical force on the urethral wall. This mechanical injury triggers a wound-healing cascade: inflammation → fibroblast activation → collagen deposition → scar contraction. Repeated cycles of injury and healing can amplify fibrosis, progressively stiffening the urethral segment and narrowing the lumen despite repeated luminal widening attempts.

Alteration of tissue planes and blood supply

Repeated instrumentation may damage the submucosal vasculature and disrupt normal tissue planes. Compromised blood supply impairs healthy mucosal regeneration and favors scar tissue formation, which is less pliable and more likely to re-stenose.

Iatrogenic extension and false passages

Blind dilatation, particularly when performed without visual guidance or experience, can cause mucosal tears, extravasation and false tracts. These create irregular lumens and areas of devitalized tissue that are prone to infection and poor healing.

Biologic remodeling

Some studies indicate that repeated interventions can alter the histology of strictures—more collagen types associated with permanent scarring and fewer elastin fibers—producing tissue that is less amenable to future endoscopic repair and more likely to require graft-based reconstruction.

Clinical evidence: do repeated dilatations actually worsen outcomes?

Recurrence rates rise with repetition

Published series and systematic reviews consistently show that the success of a single DVIU or dilation is limited, and the likelihood of long-term patency declines with repeated procedures. Reported recurrence rates after a single endoscopic intervention span widely (10–90%), reflecting heterogeneity in patient selection, stricture characteristics and follow-up; however, multiple analyses show that repeated endoscopic treatments are less likely to succeed than initial procedures and that each subsequent endoscopic attempt yields diminishing returns.

Evidence that repeated endoscopy changes stricture anatomy and complicates reconstruction

Several cohort studies have documented that patients who undergo multiple endoscopic interventions before definitive referral more commonly present with longer strictures and worse tissue quality at urethroplasty, which translates into more complex repairs or staged procedures. A pivotal study observed that endoscopic treatments were associated with increasing stricture length and complexity, and that each prior urethrotomy increased the hazard of failure after subsequent urethroplasty. These findings suggest a dose–response relationship between the number of endoscopic procedures and adverse reconstructive outcomes.

Which data support early reconstruction over repeated endoscopy?

Major guideline-producing bodies now recommend offering urethroplasty rather than repeated endoscopic management for recurrent anterior urethral strictures. The AUA’s urethral stricture guideline amendment and EAU guidance note that repeated DVIU or dilation is unlikely to produce durable results for many patients and recommend earlier definitive reconstruction for recurrent disease. These guidelines derive from the body of cohort evidence documenting superior long-term patency after urethroplasty and the diminishing effectiveness of repeated endoscopic techniques.

How much damage? Quantifying the effect — what studies show

Stricture length and complexity

Delayed referral for urethroplasty after multiple endoscopic procedures is associated with longer strictures at reconstruction. Viers et al. and other groups reported that repeated endoscopic interventions correlate with increased stricture length and higher likelihood of requiring grafts or staged repairs, which are inherently more complex than single-stage repairs for short strictures.

Impact on urethroplasty outcomes

While urethroplasty remains highly effective, some analyses suggest that a greater number of prior endoscopic procedures may be associated with a small but measurable increase in the risk of urethroplasty failure—likely reflecting worsened tissue quality and more complex disease at the time of reconstruction. Nonetheless, even after failed endoscopic management, modern urethroplasty outcomes remain favorable; the key clinical point is that outcomes and complexity are usually better if reconstruction is offered earlier rather than after many repeated dilations.

Patient-centered outcomes and complications

Repeated instrumentation exposes patients to repeated anesthesia, procedural discomfort, infection risk, and time off work. Recurrent LUTS, UTIs, and psychological burden of repeated failures contribute substantially to morbidity. Although severe complications (like fistula or urethrocutaneous extravasation) are uncommon, the cumulative risk rises with repeated procedures.

Are there exceptions? When repeated endoscopic treatment may still be reasonable

While the trend favors earlier urethroplasty for recurrent strictures, endoscopic treatment retains a place in management:

• Short, primary, soft bulbar strictures (<1–2 cm) in medically unfit patients may be satisfactorily managed with a single DVIU or dilation.
• Temporizing measures: urgent decompression in acute retention or when immediate urethroplasty is contraindicated.
• Patient preference or limited access to reconstructive services: in resource-limited settings, repeated dilatations may be the only realistic option.
• Adjunctive strategies (see below) may improve outcomes after endoscopic treatment in selected settings.

However, clinicians must counsel patients honestly about the lower long-term success and the potential that repeated endoscopic therapy may complicate later definitive reconstruction.

Adjuncts and innovations aimed at reducing recurrence after endoscopic therapy

Intralesional agents (e.g., corticosteroids, mitomycin C)

Intralesional corticosteroid injection at the time of DVIU has been tested to reduce scar formation, with mixed evidence. Mitomycin C—an anti-fibrotic agent—has been studied in combination with DVIU, with some studies suggesting reduced recurrence; systematic reviews indicate potential benefit but call for larger randomized trials to confirm efficacy and safety.

Drug-coated balloons and endoscopic technologies

Drug-eluting or drug-coated balloon dilators aim to combine mechanical dilation with local delivery of anti-fibrotic or anti-proliferative drugs to reduce restenosis. Early data are promising but limited; these technologies are not yet standard of care and require larger, long-term studies. Laser urethrotomy and optical internal urethrotomy have similar short-term outcomes to cold-knife DVIU, with potential differences in short-term recurrence that are still being evaluated.

Self- or clean intermittent catheterization (CIC) after DVIU

Some programs recommend patient-performed intermittent self-dilatation or CIC following dilation to maintain patency. Evidence suggests this approach may prolong symptom-free intervals for certain patients, especially those unwilling or unfit for urethroplasty, but it requires patient motivation and has its own risks (infection, urethral trauma). Guidelines consider CIC an option in selected patients as a temporizing or maintenance strategy.

Guidelines and consensus statements — the current standard of care

• AUA (amendment 2023): recommends offering urethroplasty instead of repeated endoscopic management for recurrent anterior urethral strictures. The guideline acknowledges that DVIU/dilation may be acceptable for short naïve strictures but discourages repeated cycles of endoscopic therapy in most recurrent cases.
• EAU: emphasizes individualized care, but also highlights the limited durability of repeated DVIU and supports early reconstructive referral for recurrent or complex strictures.

These guideline positions reflect the balance of evidence: while endoscopic treatment is useful in selected situations, repeated endoscopy as a default strategy for recurrent strictures is no longer endorsed by major bodies.

Practical clinical recommendations — an evidence-based approach

1. Initial evaluation: obtain a thorough history, uroflowmetry, retrograde urethrogram (RUG) and flexible cystoscopy to define stricture length, location and severity—information that will guide whether endoscopic or reconstructive treatment is appropriate.
2. Primary endoscopic therapy: consider DVIU or dilation for short (<2 cm), soft bulbar strictures in patients who prefer minimally invasive treatment and accept lower long-term durability. Counsel patients about recurrence risk.
3. Limit repeated endoscopic attempts: if the stricture recurs after a single endoscopic treatment, discuss urethroplasty early. Repeating DVIU/dilation more than once or twice should prompt referral to reconstructive urology because of diminishing success rates and possible worsening of the stricture.
4. Use adjuncts selectively: consider intralesional agents or CIC in highly selected patients or where urethroplasty is not feasible; be honest about limited and heterogeneous evidence.
5. biEarly referral: when a patient has recurrent disease, long-segment stricture, lichen sclerosus, or prior pelvic trauma, refer early for reconstructive evaluation—urethroplasty offers a more durable cure and may avoid escalation of complexity from repeated endoscopic work.

Cost, access, and global practice patterns

In low- and middle-income settings, repeated dilatation is often practiced because it is cheaper, easier to perform, and more accessible than urethroplasty. However, the cumulative cost of repeated procedures, lost workdays, and repeated complications may offset short-term savings. Health systems should weigh investment in reconstructive training and resources, which produce durable cures and may be cost-saving over time. Strategies such as telemedicine referral networks, visiting specialist programs, and training initiatives can reduce delays to definitive care.

Research gaps and future directions

• High-quality randomized trials comparing early urethroplasty with repeated endoscopic management in well-defined patient cohorts are limited and would strengthen evidence for timing decisions.
• Standardized histopathologic studies comparing tissue changes after repeated endoscopic injury versus naïve strictures could help quantify biologic damage and identify molecular targets to prevent fibrosis.
• Large multicenter registries capturing the number of prior endoscopic procedures, stricture characteristics, PROMs and long-term reconstructive outcomes will improve prognostic models and patient counseling.
• Novel localized anti-fibrotic therapies (e.g., drug-eluting balloons, local gene therapies) require well-designed clinical trials before routine adoption.

Balanced perspective — not an absolute prohibition but a call for prudence

It is important to avoid oversimplified statements. Repeated endoscopic dilatations do not inevitably “ruin” the urethra; many patients undergo multiple procedures without catastrophic outcomes. However, the preponderance of evidence shows that repeated endoscopic interventions are associated with higher recurrence rates, may lengthen strictures and worsen tissue quality, and can complicate later reconstructive surgery. The modern, evidence-based stance therefore favors restraint: use endoscopic treatment thoughtfully, limit repeat attempts, and refer patients for urethroplasty when recurrence occurs or when stricture complexity indicates reconstruction is the durable option. Shared decision-making—informing patients of risks, benefits, alternatives and likely long-term outcomes—is essential to good care.

Conclusion — practical message for clinicians and researchers

Repeated endoscopic dilatation and DVIU are useful tools that can rapidly relieve obstruction and serve as temporizing measures. But repeated procedures impose biological and clinical consequences: increased fibrosis, potential stricture lengthening, risk of iatrogenic injury, and higher complexity for later urethroplasty. Contemporary guidelines and a growing evidence base therefore encourage timely referral for reconstructive surgery after recurrence rather than a prolonged cycle of repeated endoscopic interventions. Clinicians should individualize care, discuss realistic expectations with patients, and include reconstructive urology consultation early in the pathway for recurrent or complex urethral strictures. Future work should aim to quantify histologic damage from repeated instrumentation, refine adjunctive anti-fibrotic therapies, and expand access to reconstructive expertise in settings where resources are limited.

Best Hospital for Treatment of Urethral Stricture in Rajasthan – Institute of Urology, C Scheme, Jaipur

At the Institute of Urology, Jaipur, patients with urethral stricture receive coordinated, evidence-based care — from office-based assessment and endoscopic management to advanced reconstructive urethroplasty when indicated. Dr. M. Roychowdhury and Dr. Rajan Bansal bring extensive experience in treating urethral strictures across the full spectrum: conservative and endoscopic care for suitable patients, and definitive open reconstructive techniques (excision and primary anastomosis, buccal mucosa graft urethroplasty, staged reconstructions) for recurrent or complex disease.

The Institute provides a one-stop facility—outpatient consultation, imaging and diagnostics (uroflowmetry, RUG, cystoscopy), metabolic and laboratory services, operating theatres for endourology and reconstructive surgery, and postoperative rehabilitation—ensuring patients benefit from a streamlined, patient-centered pathway from diagnosis to durable cure.

References

• AUA Urethral Stricture Guideline (amendment 2023) — recommendation to offer urethroplasty rather than repeated endoscopic management for recurrent anterior strictures.
• Viers BR et al., “Delayed reconstruction of bulbar urethral strictures is associated with multiple interventions” — demonstrates association between repeated endoscopy and increased stricture length/complexity.
• Pang KH et al., Systematic review/meta-analysis of adjuncts to endoscopic treatments — discusses limits of DVIU/dilation and potential adjuncts.
• Moynihan MJ et al., “Endoscopic treatments prior to urethroplasty: trends in practice” — documents practice patterns and guideline implications.
• Mershon JP et al., “Recurrent anterior urethral stricture: challenges and solutions” — comprehensive review of recurrence and management strategies.